Telomir Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Telomir Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $6.31K, a 86.79% decline year-over-year.
- Telomir Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $5.50M.
- Telomir Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $47.77K.
- Telomir Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $1.00M.
- Telomir Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2025 was $6.55M, a 4.09% decline from fiscal 2024.
- Telomir Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2024 was $6.83M, a 650.88% increase from fiscal 2023.
- Telomir Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2023 was $910.00K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $6.31K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $6.55M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $5.50M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $47.77K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $6.83M 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.83M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $5.83M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-03-31 | $5.83M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | $910.00K 10-K · filed 2025-02-04 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |